Long awaited South Korea-US Free Trade Agreement deal concluded

7 December 2010

US President Barack Obama last Friday announced the successful resolution of the outstanding issues with the US-Korea trade agreement, setting the stage for consideration of the agreement by Congress in the coming months.

He said: “I am very pleased that the United States and South Korea have reached agreement on a landmark trade deal that is expected to increase annual exports of American goods by up to $11 billion and support at least 70,000 American jobs. Last month in Seoul I directed our negotiators to achieve the best deal for American workers and companies, and this agreement meets that test.”

The US/Korea FTA will remove tariffs on 95% of goods traded between the two countries within five years, a move which the US International Trade Commission estimates will increase US exports to Korea by up to $11 billion a year. The initial FTA was signed in June 2007 but its ratification has been deadlocked until now due to concerns relating to automobiles, beef and agriculture.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical